Director Commercial Strategic Sourcing
Mineralys Therapeutics
Director Commercial Strategic Sourcing
Mineralys Therapeutics
Clinical-stage biopharma targeting aldosterone synthesis
“Mineralys Therapeutics is a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone. Its initial product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor. Mineralys is headquartered in Radnor, Pennsylvania. For more information, please visit https://mineralystx.com. Follow Mineralys on LinkedIn, Twitter and Bluesky”
Mineralys is a fully remote company.
Director, Commercial Strategic Sourcing
The Director, Commercial Strategic Sourcing will lead and manage all aspects of strategic sourcing for commercial categories, including Media Planning & Buying, Marketing Agencies, Market Research, Patient Support Programs, Trade Shows, and Promotions. This role is accountable for developing and executing sourcing strategies that deliver measurable value, mitigate risk, and align with business objectives. The position partners with executive leadership, finance, and cross-functional teams to optimize spend, improve supplier performance, and ensure compliance with corporate policies.
This position will report into the Sr. Director, Vendor Management.
Key Responsibilities
Qualifications
Travel
• 10% for occasional team and company meetings
This position is eligible for standard Company benefits including medical, dental, vision, time off and 401K, as well as participating in Mineralys incentive plans are contingent on achievement of personal and company performance. Actual compensation may vary from posted hiring range based on geographic location, work experience, education, and/or skill level.
US Salary Range: $200,000- $220,000
#LI-Remote
Clinical-stage biopharma targeting aldosterone synthesis
Mineralys Therapeutics develops targeted treatments for diseases driven by dysregulated aldosterone, aiming to control blood pressure and prevent organ damage, led by lorundrostat. Lorundrostat is an oral aldosterone synthase inhibitor that blocks the CYP11B2 enzyme to lower aldosterone production, designed to reduce blood pressure with minimal cortisol disruption due to high selectivity. Compared with older non-selective MRAs, it lowers side effects by focusing on aldosterone synthesis rather than receptor blockade. The company's goal is to advance lorundrostat through late-stage trials toward regulatory approval and commercialization, while exploring expanded uses in CKD and OSA for a potential multi-hundred-billion market.
Explore more opportunities at Mineralys Therapeutics